JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 201521-02-2022
21-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Open Offer
Centrum Capital Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulations 3(1) and 4 read with Regulations 13(1), 14 and 15(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI (SAST) Regulations") for the attention of the eligible Public Shareholders of Jagsonpal Pharmaceuticals Ltd ("Target Company").21-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - TO RECORD AND RATIFY SUPPLY AGREEMENT WITH RELATED PARTY
TO RECORD AND RATIFY SUPPLY AGREEMENT WITH RELATED PARTY18-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Appointment Of Chief Financial Officer Of The Company
Appointment of Chief Financial Officer of the Company11-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Results For The Quarter And Nine Months Ended 31.12.2021. The Board Meeting Was Concluded At 1315 Hours.
Results for the quarter and nine months ended 31.12.2021. The Board Meeting was concluded at 1315 hours.11-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON FEBRUARY 11TH, 2022.
This is to intimate that the Board of Directors of the Company at their meeting held today, (i.e. Friday, the 11th Day of February, 2022), have inter alia, approved and taken on record the following: 1. The Un-audited Financial Results for the quarter and nine months ended 31st December, 2021; 2. Limited Review Report on the Un-audited Financial Results for the said quarter; 3. Took note of Resignation of Mr. Sanjiv Kumar Dudeja from the position of Chief Financial Officer of the Company; 4. Appointment of Mr. S.V. Subha Rao as the Chief Financial Officer with effect from 11th February, 2022; 5. Other agenda items.11-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Nine Months Ended 31 December, 2021.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 ,inter alia, to consider and approve 1. The Unaudited Financial Results for the quarter and nine months ended 31.December.2021; 2. The Limited Review Report on Un-Audited Financial Results of the Company for the quarter ended 31th December, 2021; 3. The appointment of Chief Financial Officer of the Company; 4. Any other agenda item as place before the Board.03-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
In terms of the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Mr. Sanjiv Kumar Dudeja, due to personal preoccupation, has resigned from his position of Chief Financial Officer (CFO) of the Company w.e.f. February 01, 2022.01-02-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Shareholding for the Period Ended December 31, 2021
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here20-01-2022
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Cancellation of Board Meeting
The Board Meeting to be held on 27/01/2022 Stands Cancelled.19-01-2022